Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction

Journal of the American College of Cardiology

Volumn 44, Issue 6, 2004, Pages 1187-1193

  Ernst, Nicolette M S K J ^a   Suryapranata, Harry ^a   Miedema, Kor ^a   Slingerland, Robbert J ^a   Ottervanger, Jan Paul ^a   Hoorntje, Jan C A ^a   Gosselink, A T Marcel ^a   Dambrink, Jan Henk E ^a   De Boer, Menko Jan ^a   Zijlstra, Felix ^b   Van't Hof, Arnoud W J ^a,c  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Isala Klinieken   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HEART INFARCTION; HEMATOMA; HUMAN; MALE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME; TYROSINE;

EID: 4444317097     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.050     Document Type: Article

References (24)

1. S.R. Steinhubl, J.D. Talley, G.A Braden Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study Circulation 103 2001 2572 2578
2. The TARGET Investigators Do tirofiban and reopro give similar efficacy trial N Engl J Med 344 2001 1888 1894
3. R.A. Harrington, E.M. Ohman, K.N Sigmon Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states (abstr) Circulation 92 Suppl I 1995 I488
4. D. Soffer, I. Moussa, M Karatepe Sub-optimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris Am J Cardiol 91 2003 872 875
5. S.S. Kabbani, A. Aggarwal, E.F. Terrien, P.M. DiBattiste, B.E. Sobel, D.J. Schneider Sub-optimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions Am J Cardiol 89 2002 647 650
6. W.B. Batchelor, T.R. Tolleson, Y Huang Randomised comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial Circulation 106 2002 1470 1476
7. Ver Lee P, Ward T, Cunningham R. Incremental bolus dosing of tirofiban guided by rapid platelet function assay to achieve greater levels of inhibition of platelet aggregation during percutaneous coronary intervention (abstr). Am J Cardiol 2001;88 Suppl:12G.
8. DeBoard D, Jack J, Wason L, et al. Biologic variability of response to glycoprotein IIb/IIIa platelet inhibitors supports in-laboratory rapid platelet function assay to optimise platelet inhibition during percutaneous coronary intervention (abstr). Am J Cardiol 2001;88 Suppl:97G.
9. A.S. Kini, M. Richard, J Suleman Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study) Am J Cardiol 90 2002 526 529
10. D.J. Schneider, H.C. Herrmann, N Lakkis Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am J Cardiol 90 2002 1421 1423
11. G.B. Danzi, C. Capuano, M. Sesana, R. Baglini Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention Curr Med Res Opin 19 2003 28 33
12. N. Lakkis, N. Lakiss, J. Bobek, J. Farmer Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited Catheter Cardiovasc Intervent 56 2002 474 477
13. D.G. Carville, P.A. Schleckser, K.E. Guyer, M. Corsello, M.M. Walsh Whole blood platelet function assay on the ICHOR point-of-care haematology analyser J Extra Corpor Technol 30 1998 171 177
14. N.M. Lakkis, S. George, E. Thomas, M. Ali, K. Guyer, D. Carville Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors Catheter Cardiovasc Intervent 53 2001 346 351
15. J.H. Chesebro, G. Knatterud, R Roberts Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge Circulation 76 1987 142 154
16. C.M. Gibson, C.P. Cannon, W.L Daley TIMI frame count: a quantitative method of assessing coronary artery flow Circulation 93 1996 879 888
17. A.W.J. van t Hof, A. Liem, H. Suryapranata, J.C.A. Hoorntje, M.J. de Boer, F. Zijlstra Zwolle Myocardial Infarction Study Group Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade Circulation 97 1998 2302 2306
18. R.M. Scarborough, N.S. Kleiman, D.R. Phillips Platelet glycoprotein IIb/IIIa antagonists What are the relevant issues concerning their pharmacology and clinical use? Circulation 100 1999 437 444
19. R.A. Harrington, N.S. Kleiman, K Kottke-Marchant Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention Am J Cardiol 76 1995 1222 1227
20. S.R. Steinhubl, K. Kottke-Marchant, D.J Moliterno Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention Circulation 100 1999 1977 1982
21. D.J. Kereiakes, T.M. Broderick, E.M Roth Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention Am J Cardiol 84 1999 391 395
22. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
23. I. Mller, M. Seyfarth, S Rdiger Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement Heart 85 2001 92 93
24. J.W. Smith, S.R. Steinhubl, A.M Lincoff Rapid platelet-function assay: an automated and quantitative cartridge-based method Circulation 99 1999 620 625